NCT05895643View on ClinicalTrials.gov

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Alcohol AbuseAlcohol AddictionAlcohol DependenceAlcohol Use Disorder
Interventions
DRUG

Semaglutide Injectable Product

Once weekly injections s.c with semaglutide (Wegovy)

DRUG

Placebo

Once weekly injections s.c with placebo (BD Posiflush)

Trial Locations (1)

2000

Psychiatric Center Copenhagen, Frederiksberg Hospital, Frederiksberg

All Listed Sponsors
collaborator

Neurobiology Research Unit

UNKNOWN

lead

Psychiatric Centre Rigshospitalet

OTHER

NCT05895643 - Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? | Biotech Hunter | Biotech Hunter